MSI and a subgroup of MSS patients have high intratumoral adaptive immune gene expression
Functional effector anti-frameshift mutation CTLs kill tumor cells in MSI patients
Genetic evidence of immunoediting in human CRC, in particular for MSI patients
Immunoscore gives an indicator of tumor recurrence and survival beyond MSI staging